J
James J. Hanyok
Researcher at Daiichi Sankyo
Publications - 13
Citations - 4900
James J. Hanyok is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 7 publications receiving 4211 citations.
Papers
More filters
Journal ArticleDOI
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano,Christian T. Ruff,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Jonathan L. Halperin,Albert L. Waldo,Michael D. Ezekowitz,Jeffrey I. Weitz,Witold Rużyłło,Mikhail Ruda,Yukihiro Koretsune,Joshua Betcher,Minggao Shi,Laura T. Grip,Laura T. Grip,Shirali P. Patel,Indravadan Patel,James J. Hanyok,Michele Mercuri,Elliott M. Antman,Elliott M. Antman,Abstr Act,Abstr Act +23 more
TL;DR: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
Journal ArticleDOI
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Christian T. Ruff,Robert P. Giugliano,Elliott M. Antman,Sharon Crugnale,Tomas S. Bocanegra,Michele Mercuri,James J. Hanyok,Indravadan Patel,Minggao Shi,Dan Salazar,Carolyn H. McCabe,Eugene Braunwald +11 more
TL;DR: In this paper, a phase 3 comparison of the novel oral factor Xa inhibitor edoxaban to warfarin for the prevention of thromboembolism in patients with atrial fibrillation was conducted.
Journal ArticleDOI
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
Steven E. Nissen,E. Murat Tuzcu,H. Bryan Brewer,Ilke Sipahi,Stephen J. Nicholls,Peter Ganz,Paul Schoenhagen,David D. Waters,Carl J. Pepine,Tim Crowe,Michael H. Davidson,John E. Deanfield,Lisa Wisniewski,James J. Hanyok,Laurent M. Kassalow +14 more
TL;DR: For patients with coronary disease, treatment with an ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular ultrasonography.
Journal ArticleDOI
S100: quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed flt3-itd+ aml
Harry P. Erba,Pau Montesinos,Ranka Vrhovac,Elżbieta Patkowska,H. J. Kim,Pavel Zak,P.-N. Wang,T. Mitov,James J. Hanyok,Li Liu,Aziz Benzohra,Arnaud Lesegretain,Jorge E. Cortes,Alexander E. Perl,Mikkael A. Sekeres,Hervé Dombret,S. Amadori,J. Wang,Mark J. Levis,Richard F. Schlenk +19 more
Journal ArticleDOI
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial
Bram J. Geller,Robert P. Giugliano,Eugene Braunwald,Sabina A. Murphy,James J. Hanyok,Jianqing Jin,Michele Mercuri,Elliott M. Antman,Christian T. Ruff +8 more
TL;DR: In this paper, the authors performed a prespecified analysis in 21,105 patients with AF enrolled in the ENGAGE AF-TIMI 48 trial, which compared two once-daily regimens of edoxaban with warfarin for the prevention of stroke and systemic embolic events (SEEs).